UroGen Pharma Ltd. — Director's Dealing 2023

Feb 28, 2023

SEC Form 4/A — Form 4/A

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-06-06

Reporting Person: Nussbaum Ran (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-06	Ordinary Shares	M	1030	$5	Acquired	1434958	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-06	Stock Option (right to buy)	$5	M	1030	Disposed	2022-09-01	Ordinary Shares (1030)	Indirect

Footnotes

F1: On August 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,433,928 shares of securities beneficially owned following reported transaction instead of 1,434,958 shares.

F2: On August 25, 2022, the reporting person filed a Form 4 that inadvertently list the expiration date as August 31, 2022.